It focuses on interrupting the cycle of BRASH phenomenon with the following: 1) withdrawing AV-nodal blocking agents and reversal therapy with glucagon when patient is hemodynamically unstable; 2) hyperkalemia correction with calcium gluconate, insulin-dextrose therapy, sodium zirconium cyclosilicate [3,8]; 3) providing hemodynamic support and improving renal perfusion with vasopressors [1,3,8]; 4) temporary or permanent cardiac pacing [9]; and 5) initiating renal replacement therapy for refractory hyperkalemia [6,10]. Here, INS is linked to Hyperkalemia.